Eisai (company)

Eisai Co., Ltd.

Native name	エーザイ株式会社
Type	Public KK
Traded as	: TOPIX 100 Component Nikkei 225 Component
Industry	Pharmaceuticals
Founded	(December 6, 1941; 75 years ago (1941-12-06))
Founder	Toyoji Naito
Headquarters	4-6-10 Koishikawa, Bunkyo-ku, Tokyo 112-8088, Japan
Key people	Haruo Naito (President and CEO)
Products	Halaven Aricept Pariet Banzel Zonegran Fycompa Zebinix
Revenue	US$ 5.82 billion (FY 2013) (JPY 600.4 billion) (FY 2013)
Net income	US$ 320 million (FY 2013) (JPY 33 billion) (FY 2013)
Number of employees	10,419 (consolidated, as of March 31, 2014)
Website	Official website
Footnotes / references

US$ 5.82 billion (FY 2013)

US$ 320 million (FY 2013)

Eisai Co., Ltd. (エーザイ株式会社, Ēzai Kabushiki-gaisha^?) is a Japanese pharmaceutical company headquartered in Tokyo, Japan. It has some 10,000 employees, among them about 1,500 in research. Eisai is listed on the and is a member of the Topix 100 and Nikkei 225 .

Nihon Eisai Co. Ltd. was established in 1941. In 1944, merger with Sakuragaoka Research Laboratory resulted in creation of Eisai Co. Ltd. The American subsidiary of the company, Eisai Inc., was established in 1995.

In 1996, Eisai received approval from the United States Food and Drug Administration (USFDA) for Aricept (donepezil), a drug discovered in the company's labs and co-marketed with Pfizer. Three years later in 1999, the company received USFDA approval for Aciphex (rabeprazole), a drug co-marketed with Johnson & Johnson.